CYTH - Cyclo Therapeutics, Inc.

0.7206
0.010   1.374%

Share volume: 188,267
Last Updated: 03-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.17%

PREVIOUS CLOSE
CHG
CHG%
$0.71
0.01
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 25%
Liquidity 46%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
2.80%
2 Year
-56.33%
Key data
Stock price
$0.72
P/E Ratio 
0.00
DAY RANGE
$0.63 - $0.73
EPS 
-$1.23
52 WEEK RANGE
$0.62 - $0.76
52 WEEK CHANGE
$2.80
MARKET CAP 
22.641 M
YIELD 
N/A
SHARES OUTSTANDING 
28.696 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.33
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Scott Fine
Region: US
Website: cyclotherapeutics.com
Employees: 9
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. In addition, it sells cyclodextrins and related products to pharmaceutical, nutritional, and other industries.

Recent news